Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06786520 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults
A Phase 1 study of HIV Infections, sponsored by ViiV Healthcare.
- Active
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 3
- Study locations
NCT06786520 is a Phase 1 study of HIV Infections that is active but no longer recruiting, run by ViiV Healthcare. The registered enrollment target is 69 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06786520, a Phase 1 study of HIV Infections, is active but no longer recruiting, sponsored by ViiV Healthcare.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers.
Conditions Studied
Interventions
- DRUG CAB LA
- DRUG CAB ULA
Study Locations (3)
Alabama
- GSK Investigational Site - Mobile
Florida
- GSK Investigational Site - Coral Gables
Illinois
- GSK Investigational Site - Oak Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2025-01-17 |
| Est. Completion | 2027-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06786520
The ClinicalTrials.gov registry entry for NCT06786520 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (85% lower). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which CAB LA is the first listed.
NCT06786520 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06786520 about?
NCT06786520 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults". This study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers.
What is the current status of trial NCT06786520?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2025-01-17. Estimated completion is 2027-11-08.
What conditions does trial NCT06786520 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT06786520?
The interventions under investigation include: CAB LA (DRUG), CAB ULA (DRUG).
Who is sponsoring clinical trial NCT06786520?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06786520 being conducted?
This trial has 3 study locations across Alabama, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.